William Palo

2.1k total citations · 1 hit paper
17 papers, 1.6k citations indexed

About

William Palo is a scholar working on Surgery, Pharmacology and Nephrology. According to data from OpenAlex, William Palo has authored 17 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Surgery, 7 papers in Pharmacology and 5 papers in Nephrology. Recurrent topics in William Palo's work include Gout, Hyperuricemia, Uric Acid (5 papers), Treatment of Major Depression (3 papers) and Case Reports on Hematomas (3 papers). William Palo is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (5 papers), Treatment of Major Depression (3 papers) and Case Reports on Hematomas (3 papers). William Palo collaborates with scholars based in United States, United Kingdom and Denmark. William Palo's co-authors include Nancy Joseph‐Ridge, H. Ralph Schumacher, Michael A. Becker, Patricia MacDonald, Robert L. Wortmann, Laurent Vernillet, George G. Nomikos, David S. Baldwin, Lambros Chrones and Elin Heldbo Reines and has published in prestigious journals such as New England Journal of Medicine, Blood and Gastroenterology.

In The Last Decade

William Palo

17 papers receiving 1.5k citations

Hit Papers

Febuxostat Compared with Allopurinol in Patients with Hyp... 2005 2026 2012 2019 2005 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
    2005 983 citations Michael A. Becker, H. Ralph Schumacher et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Palo United States 10 1.2k 749 535 229 194 17 1.6k
Ja-Ryong Koo South Korea 18 488 0.4× 286 0.4× 39 0.1× 51 0.2× 207 1.1× 60 1.3k
J. W. Sear United Kingdom 18 109 0.1× 541 0.7× 38 0.1× 93 0.4× 50 0.3× 60 1.3k
N Pozet France 20 259 0.2× 176 0.2× 13 0.0× 163 0.7× 131 0.7× 86 1.1k
Peter Stewart United Kingdom 23 63 0.1× 199 0.3× 112 0.2× 81 0.4× 138 0.7× 75 1.5k
Garth Rapeport United Kingdom 20 47 0.0× 349 0.5× 31 0.1× 134 0.6× 205 1.1× 50 1.4k
Baback Roshanravan United States 21 1000 0.8× 360 0.5× 26 0.0× 29 0.1× 223 1.1× 36 1.8k
J.M. Piqué Spain 16 45 0.0× 696 0.9× 23 0.0× 246 1.1× 100 0.5× 30 1.5k
Adrian Post Netherlands 16 263 0.2× 132 0.2× 39 0.1× 22 0.1× 184 0.9× 75 997
Kamel Masmoudi France 18 105 0.1× 70 0.1× 34 0.1× 139 0.6× 88 0.5× 57 791
Gerard P. van Berge-Henegouwen Netherlands 28 29 0.0× 1.4k 1.9× 32 0.1× 87 0.4× 152 0.8× 54 2.5k

Countries citing papers authored by William Palo

Since Specialization
Citations

This map shows the geographic impact of William Palo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Palo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Palo more than expected).

Fields of papers citing papers by William Palo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Palo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Palo. The network helps show where William Palo may publish in the future.

Co-authorship network of co-authors of William Palo

This figure shows the co-authorship network connecting the top 25 collaborators of William Palo. A scholar is included among the top collaborators of William Palo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Palo. William Palo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Thiéblemont, Catherine, Yasmin Karimi, Chan Y. Cheah, et al.. (2024). Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy. Blood. 144(Supplement 1). 4491–4491. 1 indexed citations
2.
Palo, William, et al.. (2017). AODTH-003 Vedolizumab clinical and post-marketing safety experience of opportunistic infections. HighWire Press Open Archive. A200.1–A200. 1 indexed citations
3.
Feagan, Brian G., Fatima Bhayat, Javaria Mona Khalid, et al.. (2017). Incidence of Pneumonia and Other Respiratory Tract Infections with Vedolizumab Treatment for Inflammatory Bowel Disease: Clinical Trial Experience. Gastroenterology. 152(5). S580–S581. 1 indexed citations
4.
Ng, S.C., et al.. (2017). DOP024 Vedolizumab clinical and post-marketing safety experience of opportunistic infections. Journal of Crohn s and Colitis. 11(suppl_1). S41–S41. 1 indexed citations
5.
Ng, Siew C., et al.. (2017). Vedolizumab Clinical and Post-Marketing Safety Experience of Opportunistic Infections. Gastroenterology. 152(5). S575–S576. 2 indexed citations
6.
Blake, Aimee, et al.. (2017). P647 Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series. Journal of Crohn s and Colitis. 11(suppl_1). S410–S411. 2 indexed citations
7.
Baldwin, David S., Lambros Chrones, Ioana Florea, et al.. (2016). The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of Psychopharmacology. 30(3). 242–252. 138 indexed citations
8.
Nomikos, George G., et al.. (2016). Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectrums. 22(4). 348–362. 24 indexed citations
9.
Jacobsen, Paula L., Atul R. Mahableshwarkar, William Palo, et al.. (2015). Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectrums. 21(5). 367–378. 43 indexed citations
10.
Bronner, Mary P., et al.. (2009). Gastric Biopsy Results From Patients Treated With Dexlansoprazole MR, a Proton Pump Inhibitor with a Dual Delayed Release Formulation. The American Journal of Gastroenterology. 104. S5–S5. 1 indexed citations
11.
Schumacher, H. Ralph, Michael A. Becker, N. Lawrence Edwards, et al.. (2006). Magnetic resonance imaging in the quantitative assessment of gouty tophi. International Journal of Clinical Practice. 60(4). 408–414. 49 indexed citations
12.
Colwell, Hilary H., Barbara Hunt, David J. Pasta, et al.. (2006). Gout Assessment Questionnaire: initial results of reliability, validity and responsiveness. International Journal of Clinical Practice. 60(10). 1210–1217. 36 indexed citations
13.
14.
Becker, Michael A., H. Ralph Schumacher, Robert L. Wortmann, et al.. (2005). Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. New England Journal of Medicine. 353(23). 2450–2461. 983 indexed citations breakdown →
15.
Schumacher, H. Ralph, et al.. (2005). Tophaceous gout: quantitative evaluation by direct physical measurement.. PubMed. 32(12). 2368–72. 39 indexed citations
16.
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ja-Ryong Koo Breakdown of academic impact, for papers by J. W. Sear Breakdown of academic impact, for papers by N Pozet Breakdown of academic impact, for papers by Peter Stewart Breakdown of academic impact, for papers by Garth Rapeport Breakdown of academic impact, for papers by Baback Roshanravan Breakdown of academic impact, for papers by J.M. Piqué Breakdown of academic impact, for papers by Adrian Post Breakdown of academic impact, for papers by Kamel Masmoudi Breakdown of academic impact, for papers by Gerard P. van Berge-Henegouwen
Rankless by CCL
2026